Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
30232144
DOI
10.1158/1535-7163.mct-18-0696
PII: 1535-7163.MCT-18-0696
Knihovny.cz E-zdroje
- MeSH
- arginin farmakologie MeSH
- donory oxidu dusnatého farmakologie MeSH
- doxorubicin analogy a deriváty farmakologie MeSH
- hydroxymočovina farmakologie MeSH
- makromolekulární látky farmakologie MeSH
- modely nemocí na zvířatech MeSH
- myši MeSH
- nádory krevní zásobení patologie MeSH
- nanočástice chemie MeSH
- nanomedicína * MeSH
- nitroglycerin farmakologie MeSH
- oxid dusnatý biosyntéza MeSH
- permeabilita MeSH
- potkani Sprague-Dawley MeSH
- protinádorové látky farmakologie MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- arginin MeSH
- donory oxidu dusnatého MeSH
- doxorubicin MeSH
- hydroxymočovina MeSH
- makromolekulární látky MeSH
- nitroglycerin MeSH
- oxid dusnatý MeSH
- pirarubicin MeSH Prohlížeč
- protinádorové látky MeSH
Enhanced permeability and retention (EPR) effect-based nanomedicine is a promising strategy for successful anticancer therapy. The EPR effect is based on tumor blood flow. Because advanced large tumors, as frequently seen in clinical settings, are heterogeneous, with regions of defective vasculature and blood flow, achieving the desired tumor drug delivery is difficult. Here, we utilized the EPR effect to increase drug delivery. To augment the EPR effect for improved therapeutic effects of nanomedicine, we exploited vascular mediators-the nitric oxide (NO) generators nitroglycerin (NG), hydroxyurea, and l-arginine. These compounds generate NO in tumors with relatively high selectivity. Using different nanosized drugs in our protocol significantly increased (1.5-2 times) delivery of nanomedicines to different solid tumor models, along with markedly improving (2-3-fold) the antitumor effects of these drugs. Also, in 7,12-dimethylbenz[a]anthracene-induced advanced end-stage breast cancer, often seen in clinical settings, 2 mg/kg polymer-conjugated pirarubicin (P-THP) with NG (0.2 mg/mouse) showed better effects than did 5 mg/kg P-THP, and 5 mg/kg P-THP used with NG resulted in cures or stable tumors (no tumor growth) for up to 120 days. Moreover, in a murine autochthonous azoxymethane/dextran sulfate sodium-induced colon cancer model, NO donors markedly improved the therapeutic effects of P-THP even after just one injection, results that were comparable with those achieved with three weekly P-THP treatments. These findings strongly suggest the potential usefulness of NO donors as EPR effect enhancers to improve the therapeutic efficacy of nanomedicines.
BioDynamics Research Foundation Kumamoto Japan
Department of Microbiology Graduate School of Medical Sciences Kumamoto University Kumamoto Japan
Faculty of Pharmaceutical Sciences Sojo University Kumamoto Japan
Institute of Macromolecular Chemistry Czech Academy of Sciences Prague Czech Republic
Citace poskytuje Crossref.org
HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery